These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 35352187)

  • 1. Rickets guidance: part II-management.
    Haffner D; Leifheit-Nestler M; Grund A; Schnabel D
    Pediatr Nephrol; 2022 Oct; 37(10):2289-2302. PubMed ID: 35352187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets.
    Baroncelli GI; Grandone A; Aversa A; Sessa MR; Pelosini C; Michelucci A; Toschi B; Manca M; Isola A; Comberiati P
    Eur J Med Genet; 2024 Aug; 70():104958. PubMed ID: 38950880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approach to Hypophosphatemic Rickets.
    Ackah SA; Imel EA
    J Clin Endocrinol Metab; 2022 Dec; 108(1):209-220. PubMed ID: 35981346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management.
    Baroncelli GI; Mora S
    Front Endocrinol (Lausanne); 2021; 12():688309. PubMed ID: 34421819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatonins: From Discovery to Therapeutics.
    Kritmetapak K; Kumar R
    Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGF23 and Hypophosphatemic Rickets/Osteomalacia.
    Takashi Y; Kawanami D; Fukumoto S
    Curr Osteoporos Rep; 2021 Dec; 19(6):669-675. PubMed ID: 34755323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries.
    Al Juraibah F; Al Amiri E; Al Dubayee M; Al Jubeh J; Al Kandari H; Al Sagheir A; Al Shaikh A; Beshyah SA; Deeb A; Habeb A; Mustafa M; Zidan H; Mughal MZ
    Arch Osteoporos; 2021 Mar; 16(1):52. PubMed ID: 33660084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF23 and Associated Disorders of Phosphate Wasting.
    Gohil A; Imel EA
    Pediatr Endocrinol Rev; 2019 Sep; 17(1):17-34. PubMed ID: 31599133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
    Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
    Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
    Fukumoto S
    J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1).
    Bai X; Levental M; Karaplis AC
    J Clin Endocrinol Metab; 2022 Sep; 107(10):2777-2783. PubMed ID: 35896139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets.
    Harada D; Ueyama K; Oriyama K; Ishiura Y; Kashiwagi H; Yamada H; Seino Y
    J Pediatr Endocrinol Metab; 2021 Jun; 34(6):791-798. PubMed ID: 33837680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy.
    Bergwitz C; Miyamoto KI
    Pflugers Arch; 2019 Jan; 471(1):149-163. PubMed ID: 30109410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
    Athonvarangkul D; Insogna KL
    Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burosumab: Current status and future prospects.
    Goyal A; Tandon N
    Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101826. PubMed ID: 37858479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.
    Imel EA; Glorieux FH; Whyte MP; Portale AA; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Chen A; Roberts MS; Ward LM
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2990-2998. PubMed ID: 37084401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders.
    Takashi Y; Kawanami D; Fukumoto S
    Curr Opin Endocrinol Diabetes Obes; 2024 Aug; 31(4):170-175. PubMed ID: 38687287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.